Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved in the U.S. for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events, including our regulatory filings in Europe related to Cinryze, including without limitation statements related to potential regulatory timelines, the likelihood of regulatory success including our ability to address the questions regarding our relationship with Sanquin and the scope of indications for which Cinryze may be approved. The EC may view the data regarding the use of Cinryze for acute treatment and / or prevention of HAE we hav
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
(Date:1/22/2015)... AMGN ) today announced that it will report its ... 27, 2015, after the close of the U.S. financial markets. The ... community at 2 p.m. PT. Participating in the call from Amgen ... officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... , WESTON, Mass., Nov. 9 Groundbreaking articles in ... for the first time explore, in depth, ... care providers and its potential benefits for patients. , ... Aggarwal, PhD who is a member of the prestigious ...
... HEMPSTEAD, N.Y., Nov. 9 /PRNewswire/ -- On Sept. ... workers came together to save as many lives as possible ... of those 9/11 first responders. Now he is fighting to ... McCauley was diagnosed with cancer in 2006. He has undergone ...
Cached Medicine Technology:Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... together the scope of this ubiquitous but overlooked bug, ... over and over.,Even though the virus seems to be ... ,Like many other respiratory bugs, this one is most ... for the first time. Although repeat infections are thought ...
... it does, it can kill within months. Now there's a vaccine ... than a mere crutch for Rev. Jerry Burnside when he was ... faith sustained me in that, but I dreaded the process of ... caught early, but it does not respond well to standard therapies ...
... one of the most widely used disinfectants,for indoor ... decades due to it's ability to kill Bacteria,efficiently ... this,chemical might be the likely reason for the ... ,The culprit is a chemical known as trichloroamine//,(chemical ...
... A Washington University research team headed by Shrikant Anant, ... was reported in the journal, Molecular Cell. They have ... binding protein) - that makes cancer cells self-destruct. The ... grown in a test tube. Human studies aren't yet ...
... seen a sharp rise in the use of alternative treatments ... scientifically document the effects of hundreds of herbs and other ... to current, comprehensive information about these agents. ,Experts at ... created a new website which will provide up-to-date information on ...
... Raelian cult, Brigetter Boisselier, it has been observed that a ... on record. In a telephonic interview with AFP, Ms.Boisselier, president ... was born by caesarean and the birth 'went very well'.// ... human birth by cloning was carried out in secrecy, it ...
Cached Medicine News:Health News:Metapneumovirus - a common cause of adults' colds, kids' illness 2Health News:New insights into herbal supplements 2
... Loading Units With Titanium Staples ... (Single Use Reloadable Staplers With ... ILA™ 75 single-use stapler, anastomotic ... in the resection, transection, and/or ...
... The Auto Suture™ GIA™ Reloadable Staplers ... application in abdominal, gynecological, pediatric and ... and creation of anastomosis. , ... and the SGIA™ Knifeless Stapler have ...
... The PROXIMATE ILS Staplers are anastomotic ... proper matching of instrument to lumen diameter. ... detachable anvil head to improve access and ... surgeon to control tissue compression by adjusting ...
... Staplers are anastomotic staplers available in four ... to lumen diameter. The staplers permit tissue ... improve access and ease of use. The ... compression by adjusting the height of the ...
Medicine Products: